Related Experiment Videos

Focal myopathy associated with chronic intramuscular injection of piritramide

P Y Van den Bergh1, L Guettat, B C Vande Berg

  • 1Department of Neurology, Cliniques Universitaires St-Luc, University of Louvain, Brussels, Belgium.

Muscle & Nerve
|December 9, 1997
PubMed

Insights

Chronic use of piritramide injections can cause fibrotic myopathy, a condition where muscle is replaced by fibrous tissue. This study observed similar effects in rats, cautioning against prolonged piritramide use.

Area of Science:

  • Neurology
  • Pathology
  • Pharmacology

Background:

  • Piritramide is an opioid analgesic.
  • Myotoxicity of piritramide has not been previously reported.
  • Investigating potential adverse effects of piritramide is crucial for patient safety.

Observation:

  • A patient developed focal fibrotic myopathy following chronic intramuscular piritramide administration.
  • Experimental study on rat skeletal muscle was conducted to investigate piritramide myotoxicity.
  • Muscle tissue samples were analyzed for pathological changes.

Findings:

  • Chronic intramuscular piritramide administration resulted in the replacement of skeletal muscle with fibrous connective tissue in rats.
  • The observed fibrotic changes in rat muscle mirrored those found in the patient.
  • This suggests a potential myotoxic effect of piritramide.

Implications:

  • Prolonged intramuscular piritramide use may lead to debilitating fibrotic myopathy.
  • The findings warrant caution regarding the long-term administration of piritramide via intramuscular injection.
  • Further research is needed to elucidate the pathogenetic mechanism of piritramide-induced myopathy.

Related Concept Videos